Skip to main content
Equibles
NRXP logo

NRXP · NRX Pharmaceuticals, Inc. · Metrics

Track NRXP — free

Use NRXP with AI

Ask our own analyst here, or connect this data to the AI you already use.

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

Claude ChatGPT Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$3.37 -0.10 (-2.88%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“the Company has concluded that substantial doubt exists about the Company's ability to continue as a going concern for a period of at least twelve months from the date of issuance of these consolidated financial statements.”
View the 10-Q filed Aug 14, 2026
Market Cap
$151.10M
Shares
43.30M

NRXP metrics

57 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$3.47
Market cap
$151.10M

Price action

20 metrics
Price change (1W)
-1.7%
Price change (30D)
+4.2%
Price change (3M)
-15.7%
Price change (6M)
+105.3%
Price change (YTD)
+28.8%
Price change (1Y)
+32.7%
Trailing year
Price change (5Y)
—
52-week high
$4.62
52-week low
$1.68
Change from 52-week high
-24.5%
Change from 52-week low
+107.7%
Annualized volatility
87.9%
Annualized volatility (3M)
73.4%
Beta
2.1
RSI (14D)
49.3
Price vs SMA 50
-5.2%
Price vs SMA 200
+22.6%
Avg volume (3M)
1.00M
Relative volume
0.5
Average dollar volume
$3.71M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
43.30M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
44.5×
reciprocal yield 2.2%
P / book
—
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-15.5%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-08-17

Profitability

9 metrics
Gross margin
46.6%
Operating margin
-586.2%
Trailing 12 months
Net margin
-691.8%
Gross profit (TTM)
—
Operating profit (TTM)
−$19.89M
Net income (TTM)
−$23.48M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$-17.83

Growth

11 metrics
Revenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
$3.39M
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+33.2%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
—
Return on assets
-68.7%
Debt / equity
—
Current ratio
0.9
EBITDA (TTM)
−$19.70M
Free cash flow (TTM)
—
Quick ratio
0.9
Interest coverage
-17.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Cash & equivalents
$26.69M
Total assets
$34.16M
Total debt
$18.32M

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$19.77M
Capital expenditures (TTM)
$0
R&D (TTM)
$5.41M
SG&A (TTM)
$15.93M
Stock compensation (TTM)
$439,000
R&D / revenue
159.4%
Stock compensation / revenue
12.9%

Ownership (13F)

3 metrics
13F filers
48
13F filer change QoQ
+13
Institutional ownership
28.2%

Short interest

3 metrics
Short interest
20.0%
Latest settlement · 5.8 days to cover
Days to cover
5.8d
Short-squeeze score
80 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1719406 CUSIP 629444209 13F (30d) 33 filings 33 filers Visit website Investor relations